404
Hemophilia A And B Therapeutics Materials Market Report
Hemophilia A and B Therapeutics Materials Market Trends, Dynamics & Market Insights
Hemophilia A and B Therapeutics Materials Market, By Drug Type (Desmopressin, Octocogalfa, Nonacogalfa, Others), Treatment (Surgery, Prophylaxis), End-Use (Dental Clinics, Hospitals, Ambulatory Surgical Centers), and Region - COV...
Eagle Biologics, Inc. (US), Spark Therapeutics, Inc. (US), Alnylam Pharmaceuticals Inc. (US), San-gamo Therapeutics, Inc. (US), Novo Nordisk A/S (Denmark), Shire plc (US), The Chugai Pharma-ceutical Co., Ltd. (Japan), Bayer AG (Germany), CSL Behring (US) and Pfizer Inc. (US) are among the key players in the hemophilia A and B therapeutics materials market.
Increasing incidences of blood disorders is the prime factor driving the growth of hemophilia A and B therapeutics materials market.
The hospital's segment is expected to register significant growth in the hemophilia A and B therapeutics materials market in the coming years.
North America accounted for the largest share in the hemophilia A and B therapeutics materials market in 2020.
Hemophilia A and B therapeutics materials distributors, Hemophilia A and B therapeutics materials suppliers, Hemophilia A and B therapeutics materials manufacturers, Logistics organizations, Government bodies are the target audience in the hemophilia A and B therapeutics materials market.